In the last twelve months, Oxford Genetics has won six new licensing deals for its scalable gene therapy manufacturing technologies. Citing significant market traction in the last year, the company says it has been working extensively with high profile, global businesses in the biotechnology industry. This work allegedly includes strengthening the portfolio of solutions and licensable technologies in the key areas of drug and gene therapy development services. The projects being undertaken include a licence agreement with Aldevron, a leading US service provider, to bring to market the Lentiviral Plasmids created by Oxford Genetics; and a collaboration project with Sphere Fluidics to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cells. The remaining undisclosed project wins are confidential licensing arrangements with large pharmaceutical companies, where Oxford Genetics is providing its proprietary cell lines and viral vectors for the discovery and development of viral therapies. Ryan Cawood, founder and chief executive of Oxford Genetics, said: “2018 was an outstanding year for our business and we are expecting to close our financial year to 30 April 2019 showing 300% revenue growth on the prior year. We also have a strong order book for 2019/20. “Our customer base is shaping up to be an impressive collection of long-term partners and in addition, our increasing global reach is enabling us to further demonstrate our technical excellence and clear market differentiation.” The company offers a suite of novel solutions for gene therapy drug discovery, antibody therapy development and CRISPR gene editing.
Oxford Genetics will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies. The company has already begun to develop a new generation of gene-editing technology that can be used in human clinical trials and is working with partners on developing an additional type of gene therapy. The remaining agreements are confidential deals secured with large pharmaceutical firms.